Exclusivity Without Patents: The New Frontier of FDA Regulation for Genetic Materials

Author:Gregory Dolin
Position:ssociate Professor of Law, Co-Director, Center for Medicine & Law, University of Baltimore School of Law

Over the last twenty years, the legal and scientific academic communities have been embroiled in a debate about the patent eligibility of genetic materials. The stakes for both sides could not be higher. On one hand are the potential multi-billion dollar profits on the fruits of research (from newly discovered genes), and on the other is scientists’ ability to continue and expand research into... (see full summary)

    • This document is available in original version only for vLex customers

      Read this document for free by creating your vLex Open account